Intradigm awarded cancer-targeting RNAi US patent

Intradigm Corp, a US developer of targeted, systemic RNA interference therapeutics, says that the US Patent and Trademark Office has issued  the company a notice of allowance for a patent covering various aspects  of a potent siRNA sequence.

The firm says that the allowed subject matter covers a specific  double-stranded siRNA sequence that is directed against the angiogenic  pathway and which possesses therapeutic potential in the treatment of  cancer. This notice pertains to the first of a number of pending  applications covering proprietary Intradigm siRNA sequences against more  than 50 clinically-relevant targets.

As the first sequence-specific patent for which Intradigm has received  a notice of allowance, this development supplements the company's  existing patents, giving Intradigm allowed intellectual property  covering each of the three critical areas for RNAi therapeutic  development - target sequences, delivery and structural features.